DOCSLIB.ORG

The Kynurenine Pathway; a New Target for Treating Maternal Features of Preeclampsia?

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
The Kynurenine Pathway; a New Target for Treating Maternal Features of Preeclampsia? Placenta 84 (2019) 44–49 Contents lists available at ScienceDirect Placenta journal homepage: www.elsevier.com/locate/placenta The kynurenine pathway; A new target for treating maternal features of T preeclampsia? ∗ Stephanie A. Wortona, , Susan L. Greenwooda, Mark Wareinga, Alexander EP. Heazella,b, Jenny Myersa,b a Maternal and Fetal Health Research Centre, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, United Kingdom b St. Mary's Hospital, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, United Kingdom ARTICLE INFO ABSTRACT Keywords: In preeclampsia, vasospasm, oxidative stress, endothelial dysfunction, and immune dysregulation are key Preeclampsia mediators of maternal disease. A new time-of-disease treatment is needed with the potential to treat these areas Kynurenine pathway of pathophysiology. A review of the literature has indicated that metabolites of the kynurenine pathway have the Vascular dysfunction potential to; (i) induce vasorelaxation of resistance arteries and reduce blood pressure; (ii) exert antioxidant Immunoregulation effects and reduce the effects of poly-ADP ribose polymerase activation (iii) prevent endothelial dysfunction and promote endothelial nitric oxide production; (iv) cause T cell differentiation into tolerogenic regulatory T cells and induce apoptosis of pro-inflammatory Th1 cells. This has led to the hypothesis that increasing Kynurenine pathway activity may offer a new treatment strategy for preeclampsia. 1. Background incidence of maternal complications, and may safely allow gestation to be extended, thereby reducing prematurity-associated risks to the in- Despite advances in clinical care, delivery of the baby and placenta fant. remains the only cure for preeclampsia (PE). Current treatment stra- Whilst the origins of PE can often be traced to impaired spiral artery tegies aim to reduce the risk of maternal complications but do not ad- remodelling in early pregnancy, this is temporally removed from the dress the underlying pathophysiology of PE. Although maternal deaths onset of the maternal syndrome in the second half of pregnancy [4]. from PE are now rare in high-resource settings [1], concerns about The placenta communicates with the maternal immune system at the maternal safety are a common indication for delivery [2], which maternal-fetal interface and with the maternal endothelium via the transfers the burden of morbidity to the offspring. Babies born prema- release of factors into the maternal circulation. In susceptible in- turely, often in combination with fetal growth restriction, are at risk of dividuals, oxidative stress and circulating factors derived from the short-term complications, lifelong disabilities, and have a lifetime in- stressed placenta cause a systemic maternal inflammatory response, creased risk of cardiometabolic disease [3]. immune activation, endothelial cell dysfunction and vasospasm. These Thus, there remains a cogent clinical need to identify new treatment pathophysiological entities are closely linked and further drive each strategies for PE. Currently, given the absence of effective prevention or other in an escalating cycle which leads to hypertension, hypoperfusion reliable prediction of PE, a clinically useful treatment should be ap- and organ dysfunction; the maternal syndrome of PE. We sought to propriate for intervention at the time of diagnosis. At the stage in identify a therapeutic target which can apply the brakes to maternal pregnancy at which a diagnosis is made, reversing underlying pla- pathology; based on experimental evidence from other fields, the ky- centation defects is unlikely to be possible. Therefore an attractive nurenine (Kyn) pathway has been identified as a potential candidate to therapeutic option is to target drivers of maternal pathophysiology; an fulfil this role. This pathway first came to our attention duringalit- intervention to halt or retard disease progression could reduce the erature review of putative metabolites that were reduced in a Abbreviations: Ahr, Aryl hydrocarbon receptor; AT1-AA, Angiotensin II Type 1 receptor autoantibodies; BP, blood pressure; cis-WOOH, cis-hydroperoxide ((2S,3aR,8aR)-3a-hydroperoxy-1,2,3,3a,8,8a-hexahydropyrrolo[2,3-b]indole-2-carboxylic acid); FMD, flow-mediated dilatation; IDO, indoleamine 2,3-dioxygenase; KYN, kynurenine; NAD+, nicotinamide adenine dinucleotide; PARP, poly(ADP-ribose) polymerase; PE, preeclampsia; SHR, spontaneously hypertensive rat; TDO, tryptophan 2,3-dioxygenase; Th, T helper cell; TRP, tryptophan; QA, quinolinic acid ∗ Corresponding author. Maternal and Fetal Health Research Centre, 5th Floor (Research), St Mary's Hospital, Oxford Road, Manchester, M13 9WL, United Kingdom. E-mail address: [email protected] (S.A. Worton). https://doi.org/10.1016/j.placenta.2019.04.007 Received 2 January 2019; Received in revised form 8 April 2019; Accepted 30 April 2019 0143-4004/ © 2019 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY license (http://creativecommons.org/licenses/BY/4.0/). S.A. Worton, et al. Placenta 84 (2019) 44–49 [15]). In the maternal circulation, the ratio of circulating Kyn and Trp (K/T ratio) is significantly increased in normal pregnancy compared to non-pregnant women [16] and urinary excretion of Kyn pathway me- tabolites are increased accordingly [17]. In PE, despite increased in- flammation, which would be expected to stimulate Kyn pathway ac- tivity, there is reduced placental IDO expression and activity [16,18], and reduced release of Kyn by cultured placental tissue compared to normal pregnancy [5,16]. Information from several animal models has suggested a role for reduced Kyn pathway activity in PE: (i) Kyn pathway inhibition with low oral doses of the IDO inhibitor 1-me-Trp in wild-type mice in- creased maternal blood pressure (BP) [19]. (ii) Mice genetically defi- cient in IDO1 (IDO0/0) demonstrate several changes in pregnancy consistent with PE; renal endotheliosis, proteinuria and endothelial dysfunction [20]. In this model there was no significant increase in maternal BP but the usual pregnancy reduction in BP observed in wild type mice was attenuated. (iii) In a recent metabolic screen in catechol- O-methyl transferase knock-out mice, a well-established model of PE, there was a significant reduction in maternal serum Kyn[21]. 4. Vasorelaxant effects of the Kyn pathway Fig. 1. The Kynurenine pathway. A schematic of the kynurenine pathway of Within the last decade a novel role has emerged for a Kyn pathway tryptophan metabolism indicating the rate-limiting enzymatic conversion of L- metabolite as an endothelial-derived regulator of vascular tone [6,22]. Tryptophan to N-formylkynurenine. Feathered arrows indicate several meta- Whilst the vasoactive factor was initially reported to be Kyn itself [6], bolic steps. *cis-hydroperoxide ((2S,3aR,8aR)-3a-hydroperoxy-1,2,3,3a, 8,8a- this effect has recently been attributed to the action of cis-hydroper- hexahydropyrrolo [2,3-b]indole-2-carboxylic acid) [14]. oxide ((2S,3aR,8aR)-3a-hydroperoxy-1,2,3,3a, 8,8a-hexahydropyrrolo [2,3-b]indole-2-carboxylic acid) (cis-WOOH), a newly-identified inter- hypothesis-generating comparison of the placental metabolome of mediary produced by oxidatively-activated IDO [14]. women with normal pregnancy or PE [5]; this study found 0.63 fold The Kyn pathway is activated in many cellular and animal models of reduction in placental Kyn levels in PE in comparison to uncomplicated stress and systemic inflammation [6,9,10,14,23]. Hypotension observed pregnancies. The Kyn pathway has broad physiological roles which may in several pathologies (eg: malarial infection) can be attenuated by provide an opportunity to target several areas of aberrant pathophy- inhibiting IDO activity [6], indicating that inflammation-induced Kyn siology observed in PE, notably vasospasm, endothelial dysfunction pathway activity contributes to the development of hypotension in re- [6,7], oxidative stress [8,9] and immune activation [10,11](Fig. 2). sponse to inflammation. This is supported by several observations in This led to our hypothesis that intervening in PE to increase activity of humans; Kyn pathway activity, measured by K/T ratio, is inversely the Kyn pathway may ameliorate some features of the maternal pa- correlated with BP in human studies of trauma [23], obesity [24], sepsis thology. Here, we review evidence regarding functions of the Kyn [25] and PE [26]. pathway which underpin our hypothesis. We propose utilising this endogenous vasorelaxant factor in order to purposefully cause maternal vasorelaxation in hypertensive patholo- 2. The Kyn pathway gies. In PE, disturbances are evident at all levels of the vascular tree. In resistance arteries (< 400 μm) vasospasm arises due to both an in- The Kyn pathway is the principal catabolic route for the essential creased sensitivity to vasoconstrictor agents and dysfunction of en- amino acid tryptophan, which results in the de novo synthesis of nico- dothelium-dependent vasorelaxant pathways. These arteries contribute + tinamide adenine dinucleotide (NAD ) for use in cellular respiration significantly to the determination of peripheral vascular resistance due [12]. The metabolites of the Kyn pathway are shown in Fig. 1. Whilst to their large numbers and ability to regulate large changes in flow to the Kyn pathway degrades > 90% of Trp, remaining Trp is incorporated individual vascular beds. In vitro, commercially-sourced
Load more

Recommended publications
  • Expression and Regulation of the Rate-Limiting Enzymes of the Kynurenine Pathway in the Mouse Brain by Alexandra Kelly Brooks Di
    EXPRESSION AND REGULATION OF THE RATE-LIMITING ENZYMES OF THE KYNURENINE PATHWAY IN THE MOUSE BRAIN BY ALEXANDRA KELLY BROOKS DISSERTATION Submitted in partial fulfillment of the requirements for the degree of Doctor of Philosophy in Neuroscience in the Graduate College of the University of Illinois at Urbana-Champaign, 2017 Urbana, Illinois Doctoral Committee: Research Assistant Professor Robert H. McCusker, Chair Assistant Professor Andrew J. Steelman Assistant Professor Monica Uddin Professor Rodney W. Johnson P a g e | ii ABSTRACT During the mid-1900’s, early anti-depressants were developed to increase levels of catecholamines within the brain, leading to the theory that depression symptomology was a result of an imbalance of neurotransmitters within the brain. To date, the catecholamine theory of depression is still held to be the prevailing theory as selective serotonin reuptake inhibitors being the most commonly prescribed anti-depressants. However, the incidence of depression is still rising with a vast amount of patients failing to respond to current treatments, and with this knowledge, additional theories of the neurobiology of depression have arisen over the past 30 years. A leading theory is Kynurenine Pathway activation in relation to inflammation- or stress- induced depression-like behaviors. There has been a tremendous amount of data connecting activated immune system (or hypothalamic-pituitary-adrenal axis), increased kynurenine production and depression symptomology. Thus, understanding the factors that activate this
    [Show full text]
  • Tryptophan and Kynurenine Enhances the Stemness and Osteogenic Differentiation of Bone Marrow-Derived Mesenchymal Stromal Cells in Vitro and in Vivo
    materials Article Tryptophan and Kynurenine Enhances the Stemness and Osteogenic Differentiation of Bone Marrow-Derived Mesenchymal Stromal Cells In Vitro and In Vivo Hai Thanh Pham 1,2 , Mitsuaki Ono 3,*, Emilio Satoshi Hara 4,* , Ha Thi Thu Nguyen 1,2,3, Anh Tuan Dang 1,2,3, Hang Thuy Do 1,2,3, Taishi Komori 1, Ikue Tosa 1, Yuri Hazehara-Kunitomo 1,3, Yuya Yoshioka 1, Yasutaka Oida 1, Kentaro Akiyama 1 and Takuo Kuboki 1 1 Department of Oral Rehabilitation and Regenerative Medicine, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan; [email protected] (H.T.P.); [email protected] (H.T.T.N.); [email protected] (A.T.D.); [email protected] (H.T.D.); [email protected] (T.K.); [email protected] (I.T.); [email protected] (Y.H.-K.); [email protected] (Y.Y.); [email protected] (Y.O.); [email protected] (K.A.); [email protected] (T.K.) 2 Faculty of Dentistry, Hai Phong University of Medicine and Pharmacy, Haiphong 04211, Vietnam 3 Department of Molecular Biology and Biochemistry, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan 4 Department of Biomaterials, Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Sciences, Okayama 700-8558, Japan * Correspondence: [email protected] (M.O.); [email protected] (E.S.H.); Tel.: +81-86-235-7127 (M.O.); +81-86-235-6667 (E.S.H.); Fax: +81-86-222-7768 (M.O.); +81-86-235-6669 (E.S.H.) Abstract: Aging tissues present a progressive decline in homeostasis and regenerative capacities, Citation: Pham, H.T.; Ono, M.; Hara, which has been associated with degenerative changes in tissue-specific stem cells and stem cell E.S.; Nguyen, H.T.T.; Dang, A.T.; Do, niches.
    [Show full text]
  • THE ROLE of KYNURENINE, a TRYPTOPHAN METABOLITE THAT INCREASES with AGE, in MUSCLE ATROPHY and LIPID PEROXIDATION) by Helen Eliz
    THE ROLE OF KYNURENINE, A TRYPTOPHAN METABOLITE THAT INCREASES WITH AGE, IN MUSCLE ATROPHY AND LIPID PEROXIDATION) By Helen Elizabeth Kaiser Submitted to the Faculty of the Graduate School of Augusta University in partial fulfillment of the Requirements of the Degree of (Doctor of Philosophy in Cellular Biology and Anatomy) April 2020 COPYRIGHT© 2020 by Helen Kaiser ACKNOWLEDGEMENTS I wish to express my deepest gratitude to my mentor Dr. Mark Hamrick. His support and advice were invaluable to my learning and development as a scientist. I would like to especially recognize Dr. Hamrick’s honesty to data, and kindness to everyone around him. It was an honor to work as his student, and to be a part of this project. I would like to thank my committee members, Drs. Carlos Isales, Meghan McGee-Lawrence, and Yutao Liu, for their continued support, guidance, and helpful suggestions. They have helped to shape and focus this project, and have augmented my experience as a student during the development of my dissertation. Additionally, I want to recognize and thank Dr. Sadanand Fulzele for sharing his wealth of knowledge in techniques, and always keeping his door open for student’s questions. Next, a most heartfelt thanks to my lab mates: Andrew Khayrullin, Bharati Mendhe, Ling Ruan and Emily Parker. This project has been a team effort, all of them have been fundamental to its success. I further want to show my appreciation for the rest of the department of Cellular Biology and Anatomy at Augusta University. The histology core members Donna Kumiski and Penny Roon for their direct help in sectioning, and contributions to this project.
    [Show full text]
  • An Integrated Meta-Analysis of Peripheral Blood Metabolites and Biological Functions in Major Depressive Disorder
    Molecular Psychiatry https://doi.org/10.1038/s41380-020-0645-4 ARTICLE An integrated meta-analysis of peripheral blood metabolites and biological functions in major depressive disorder 1,2,3 1,2,3 1,2,3 1,3 1,3 4,5 1,3 1,3 Juncai Pu ● Yiyun Liu ● Hanping Zhang ● Lu Tian ● Siwen Gui ● Yue Yu ● Xiang Chen ● Yue Chen ● 1,2,3 1,3 1,3 1,3 1,3 1,2,3 Lining Yang ● Yanqin Ran ● Xiaogang Zhong ● Shaohua Xu ● Xuemian Song ● Lanxiang Liu ● 1,2,3 1,3 1,2,3 Peng Zheng ● Haiyang Wang ● Peng Xie Received: 3 June 2019 / Revised: 24 December 2019 / Accepted: 10 January 2020 © The Author(s) 2020. This article is published with open access Abstract Major depressive disorder (MDD) is a serious mental illness, characterized by high morbidity, which has increased in recent decades. However, the molecular mechanisms underlying MDD remain unclear. Previous studies have identified altered metabolic profiles in peripheral tissues associated with MDD. Using curated metabolic characterization data from a large sample of MDD patients, we meta-analyzed the results of metabolites in peripheral blood. Pathway and network analyses were then performed to elucidate the biological themes within these altered metabolites. We identified 23 differentially 1234567890();,: 1234567890();,: expressed metabolites between MDD patients and controls from 46 studies. MDD patients were characterized by higher levels of asymmetric dimethylarginine, tyramine, 2-hydroxybutyric acid, phosphatidylcholine (32:1), and taurochenode- soxycholic acid and lower levels of L-acetylcarnitine, creatinine, L-asparagine, L-glutamine, linoleic acid, pyruvic acid, palmitoleic acid, L-serine, oleic acid, myo-inositol, dodecanoic acid, L-methionine, hypoxanthine, palmitic acid, L-tryptophan, kynurenic acid, taurine, and 25-hydroxyvitamin D compared with controls.
    [Show full text]
  • Urinary Metabolomics to Identify a Unique Biomarker Panel for Detecting Colorectal Cancer: a Multicenter Study
    Published OnlineFirst May 31, 2019; DOI: 10.1158/1055-9965.EPI-18-1291 Research Article Cancer Epidemiology, Biomarkers Urinary Metabolomics to Identify a Unique & Prevention Biomarker Panel for Detecting Colorectal Cancer: A Multicenter Study Lu Deng1, Kathleen Ismond1,2, Zhengjun Liu3, Jeremy Constable4, Haili Wang2, Olusegun I. Alatise5, Martin R. Weiser4, T.P. Kingham4, and David Chang1,2 Abstract Background: Population-based screening programs are paring the metabolomic profiles from colorectal cancer versus credited with earlier colorectal cancer diagnoses and treat- controls. Multiple models were constructed leading to a good ment initiation, which reduce mortality rates and improve separation of colorectal cancer from controls. patient health outcomes. However, recommended screen- Results: A panel of 17 metabolites was identified as possible ing methods are unsatisfactory as they are invasive, are biomarkers for colorectal cancer. Using only two of the select- resource intensive, suffer from low uptake, or have poor ed metabolites, namely diacetylspermine and kynurenine, a diagnostic performance. Our goal was to identify a urine predictor for detecting colorectal cancer was developed with an metabolomic-based biomarker panel for the detection of AUC of 0.864, a specificity of 80.0%, and a sensitivity of colorectal cancer that has the potential for global popula- 80.0%. tion-based screening. Conclusions: We present a potentially "universal" metabo- Methods: Prospective urine samples were collected from lomic biomarker panel for colorectal cancer independent of study participants. Based upon colonoscopy and histopathol- cohort clinical features based on a North American popula- ogy results, 342 participants (colorectal cancer, 171; healthy tion. Further research is needed to confirm the utility of the controls, 171) from two study sites (Canada, United States) profile in a prospective, population-based colorectal cancer were included in the analyses.
    [Show full text]
  • Modulation of Rat Plasma Kynurenine Level by Platinum Nanoparticles and Likely Association with Oxidative Stress
    See discussions, stats, and author profiles for this publication at: https://www.researchgate.net/publication/327121906 Modulation of rat plasma kynurenine level by platinum nanoparticles and likely association with oxidative stress Article · August 2018 CITATIONS READS 2 39 5 authors, including: Oluyomi Adeyemi Oluwakemi Josephine Awakan Landmark University Landmark University 74 PUBLICATIONS 595 CITATIONS 12 PUBLICATIONS 7 CITATIONS SEE PROFILE SEE PROFILE David Adeiza Otohinoyi All Saints University 38 PUBLICATIONS 30 CITATIONS SEE PROFILE Some of the authors of this publication are also working on these related projects: Aspergillus-fermented Jatropha curcas seed cake: Proximate composition and effects on biochemical indices in Wistar rats View project Production of animal feed using Mushroom Biotechnology View project All content following this page was uploaded by David Adeiza Otohinoyi on 21 August 2018. The user has requested enhancement of the downloaded file. Volume 8, Issue 4, 2018, 3364 - 3367 ISSN 2069-5837 Oluyomi Stephen Adeyemi, Isaac Oluwafemi Olajide, Anne Adebukola Adeyanju, Oluwakemi Josephine Awakan, David Adeiza Biointerface ResearchOtohinoyi in Applied Chemistry www.BiointerfaceResearch.com Original Research Article Open Access Journal Received: 20.07.2018 / Revised: 08.08.2018/ Accepted: 12.08.2018 / Published on-line: 15.08.2018 Modulation of rat plasma kynurenine level by platinum nanoparticles and likely association with oxidative stress Oluyomi Stephen Adeyemi 1,*, Isaac Oluwafemi Olajide 1 , Anne Adebukola
    [Show full text]
  • Preferential Hydrolysis of Kynurenine Peptides F
    2 9 4 F. M. VERONESE, E. BOCCU’. C. A. BENASSI, AND E. SCOFFONE Preferential Hydrolysis of Kynurenine Peptides F. M, V e r o n e s e , E. Boccu’, C. A. B e n a s s i, and E. S c o f f o n e * Institute of Pharmaceutical Chemistry (Centro Naz. di Chimica del Farmaco e dei Prodotti Bio- logicamente Attivi del C.N.R.), and * Institute of Organic Chemistry (Centro Naz. di Chimica delle Macromolecole del C.N.R. — Sez. VIII), University of Padova (Italy) (Z. Naturforschg. 21 b, 294—300 [1969] ; eingegangen am 7. August 1968) The preferential cleavage of kynurenine peptides bonds was studied through reduction to y-(o- aminophenyl)-homoserine derivatives followed by mild acidic as well as mild alkaline hydrolysis. The reduction of keto group of kynurenine to hydroxy one was achieved by controlled potential electrolysis at —1.05 Volts. In order to understand the mechanism of hydrolysis some model com­ pounds related to kynurenine peptides were also synthesized and studied. Hydrolysis of y-(o-amino- phenyl)-homoserine peptides in acidic media is related only to the assistance of y-hydroxy function, whereas in alkaline media also aromatic amino group is involved. The conversion of tryptophan to kynurenine was These studies, already accomplished with kynu­ extensively investigated in our laboratories through renine alone, have now been extended to some kynu­ performic acid oxydation 1 and, with better results, renine peptides in 5% and 50% acetic acid. in peptides and proteins by ozonization 2’ 3 and dye As reported in Table I the examined kynurenine sensitized photooxidation 4 w ith the aim to reach a derivatives present similar half-wave potentials of preferential chemical cleavage at the tryptophan polarographic reduction as that done by kynurenine residue.
    [Show full text]
  • Tryptophan Metabolism and White Matter Integrity in Schizophrenia
    Neuropsychopharmacology (2016) 41, 2587–2595 © 2016 American College of Neuropsychopharmacology. All rights reserved 0893-133X/16 www.neuropsychopharmacology.org Tryptophan Metabolism and White Matter Integrity in Schizophrenia *,1 2,3,4 1 1 1 Joshua Chiappelli , Teodor T Postolache , Peter Kochunov , Laura M Rowland , S Andrea Wijtenburg , 1 1 1 1 5 2 Dinesh K Shukla , Malle Tagamets , Xiaoming Du , Anya Savransky , Christopher A Lowry , Adem Can , 6 1 Dietmar Fuchs and L Elliot Hong 1 2 Maryland Psychiatric Research Center, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA; Mood and 3 Anxiety Program, Department of Psychiatry, University of Maryland School of Medicine, Baltimore, MD, USA; MIRECC, VISN 5, Baltimore, MD, 4 5 USA; Rocky Mountain MIRECC for Suicide Prevention, Denver, CO, USA; Department of Integrative Physiology and Center for Neuroscience, University of Colorado Boulder, Boulder, CO, USA; 6Division of Biological Chemistry, Biocenter, Innsbruck Medical University, Innsbruck, Austria Schizophrenia is associated with abnormalities in the structure and functioning of white matter, but the underlying neuropathology is unclear. We hypothesized that increased tryptophan degradation in the kynurenine pathway could be associated with white matter microstructure and biochemistry, potentially contributing to white matter abnormalities in schizophrenia. To test this, fasting plasma samples were obtained from 37 schizophrenia patients and 38 healthy controls and levels of total tryptophan and its metabolite kynurenine were assessed. The ratio of kynurenine to tryptophan was used as an index of tryptophan catabolic activity in this pathway. White matter structure and function were assessed by diffusion tensor imaging (DTI) and 1H magnetic resonance spectroscopy (MRS).
    [Show full text]
  • Metabolite Transporters As Regulators of Immunity
    H OH metabolites OH Review Metabolite Transporters as Regulators of Immunity Hauke J. Weiss * and Stefano Angiari School of Biochemistry and Immunology, Trinity Biomedical Sciences Institute, Trinity College Dublin, Dublin 2, Ireland; [email protected] * Correspondence: [email protected] Received: 4 September 2020; Accepted: 16 October 2020; Published: 19 October 2020 Abstract: In the past decade, the rise of immunometabolism has fundamentally reshaped the face of immunology. As the functions and properties of many (immuno)metabolites have now been well described, their exchange among cells and their environment have only recently sparked the interest of immunologists. While many metabolites bind specific receptors to induce signaling cascades, some are actively exchanged between cells to communicate, or induce metabolic reprograming. In this review, we give an overview about how active metabolite transport impacts immune cell function and shapes immunological responses. We present some examples of how specific transporters feed into metabolic pathways and initiate intracellular signaling events in immune cells. In particular, we focus on the role of metabolite transporters in the activation and effector functions of T cells and macrophages, as prototype adaptive and innate immune cell populations. Keywords: cell metabolism; immunity; metabolite transporter; solute carrier; T cells; macrophages 1. Metabolites and Their Transporters: Key Players in Immunity Active metabolite transport is key for the survival of every cell. In immune cells, availability of extracellular metabolites also shapes immune responses and cellular interactions. Metabolite transporters indeed largely dictate immune cell activity by providing, or restricting, access to nutrients, and thereby determining the cellular metabolic profile [1]. For example, while glucose and amino acids (AAs) are largely imported as part of pro-inflammatory responses, fatty acid (FA) uptake has been found to drive pro-resolving, anti-inflammatory phenotypes [2].
    [Show full text]
  • Neuroinflammation and the Kynurenine Pathway in CNS
    cells Review Neuroinflammation and the Kynurenine Pathway in CNS Disease: Molecular Mechanisms and Therapeutic Implications Mustafa N. Mithaiwala 1,2 , Danielle Santana-Coelho 1,2, Grace A. Porter 1,2 and Jason C. O’Connor 1,2,3,* 1 Integrated Biomedical Sciences Program, Graduate School of Biomedical Sciences, UT Health San Antonio, San Antonio, TX 78229, USA; [email protected] (M.N.M.); [email protected] (D.S.-C.); [email protected] (G.A.P.) 2 Department of Pharmacology, Long School of Medicine, UT Health San Antonio, Mail Code 8864, San Antonio, TX 78229, USA 3 Department of Research, Audie L. Murphy VA Hospital, South Texas Veterans Heath System, San Antonio, TX 78229, USA * Correspondence: [email protected]; Tel.: +1-(210)-567-4232 Abstract: Diseases of the central nervous system (CNS) remain a significant health, social and eco- nomic problem around the globe. The development of therapeutic strategies for CNS conditions has suffered due to a poor understanding of the underlying pathologies that manifest them. Un- derstanding common etiological origins at the cellular and molecular level is essential to enhance the development of efficacious and targeted treatment options. Over the years, neuroinflammation has been posited as a common link between multiple neurological, neurodegenerative and neu- ropsychiatric disorders. Processes that precipitate neuroinflammatory conditions including genetics, infections, physical injury and psychosocial factors, like stress and trauma, closely link dysregulation Citation: Mithaiwala, M.N.; in kynurenine pathway (KP) of tryptophan metabolism as a possible pathophysiological factor that Santana-Coelho, D.; Porter, G.A.; ‘fuel the fire’ in CNS diseases. In this study, we aim to review emerging evidence that provide O’Connor, J.C.
    [Show full text]
  • Systemic L-Kynurenine Administration Partially Protects Against NMDA
    Systemic L-Kynurenine Administration Partially Protects Against NMDA, But Not Kainate-Induced Degeneration of Retinal Ganglion Cells, and Reduces Visual Discrimination Deficits in Adult Rats Christian K. Vonuerk* MichaelR. Kreutz* Evan B. Dreyer,-f and Bernhard A. Sabel* Purpose. Kynurenic acid (KYNA), an endogenous tryptophan metabolite, is an N-methyl-D- aspartate (NMDA) antagonist active at the glycine-binding site of the NMDA-receptor com- plex. The authors investigated whether systemic administration of a biochemical precursor of KYNA, L-kynurenine (L-Kyn), could block NMDA- or kainic acid (KA)-induced cell death in adult rat retinal ganglion cells (RGCs) and protect NMDA-treated animals from lesion- induced visual deficits. Methods. Rats were injected with 20-nmol NMDA or 5-nmol KA intraocularly. To quantify the number of surviving RGCs, the retrograde tracer horseradish-peroxidase was injected into the superior colliculus contralateral to the lesioned eye. Surviving RGCs were counted on wholemounted retinae in a centroperipheral gradient, as well as in the four quadrants, using a computer-assisted image analysis system. Results. The NMDA-injections resulted in an approximately 82% RGC loss in the adult rat retina compared with control retinae and a cell loss of approximately 50% in KA-treated retinae. Pretreatment with L-Kyn significantly reduced NMDA-induced RGC degeneration to values of approximately 60%, but KA toxicity was not significantly affected by L-Kyn pretreat- ment. Intraocular injections of NMDA resulted in an impairment of visual discrimination behavior, which partially recovered within a period of approximately 3 weeks. However, when treated systemically with L-Kyn, brightness discrimination was significantly improved as com- pared with NMDA-treated rats.
    [Show full text]
  • The Kynurenine Pathway As a Common Target for Ketamine and the Convergence of the Inflammation and Glutamate Hypotheses of Depression
    Neuropsychopharmacology (2013) 38, 1607–1608 & 2013 American College of Neuropsychopharmacology. All rights reserved 0893-133X/13 www.neuropsychopharmacology.org Commentary Conceptual Confluence: The Kynurenine Pathway as a Common Target for Ketamine and the Convergence of the Inflammation and Glutamate Hypotheses of Depression Andrew H Miller*,1 1 Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta, GA, USA Neuropsychopharmacology (2013) 38, 1607–1608; doi:10.1038/npp.2013.140 Two of the dominant theories regarding the development of neurotrophic factor (BDNF), which is dependent upon depression and its response (or lack thereof) to conven- glutamate stimulation of alpha-amino-3-hydroxy-5-methyl- tional antidepressant therapies involve excessive activation 4-isoxazolepropionic acid (AMPA) receptors as a result of inflammatory pathways and alterations in glutamate of ketamine’s antagonism of NMDA receptors (Duman metabolism. Increased inflammation has been demon- et al, 2012). strated in a significant subset of depressed patients, and Interestingly, inflammatory cytokines have been shown to there appears to be a special relationship between interact with glutamate pathways in several important ways, inflammation and treatment resistance (Miller et al, 2009). including decreasing the expression of glutamate transpor- Indeed, increased inflammatory markers prior to antide- ters on relevant glial elements and increasing the release of pressant treatment predict treatment non-response, glutamate from astrocytes. Glutamate released by astrocytes and patients with treatment-resistant depression exhibit has preferential access to extrasynaptic NMDA receptors, increased inflammatory markers. Moreover, clinical factors which have been shown to decrease BDNF and increase related to treatment non-response are associated with excitotoxicity (Miller et al, 2009).
    [Show full text]